Bioxcel Therapeutics (BTAI)

$1.15

-0.02

(-1.71%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.13
    $1.20
    $1.15
    downward going graph

    1.74%

    Downside

    Day's Volatility :5.7%

    Upside

    4.03%

    downward going graph
  • $1.03
    $10.43
    $1.15
    downward going graph

    10.43%

    Downside

    52 Weeks Volatility :90.12%

    Upside

    88.97%

    downward going graph

Returns

PeriodBioxcel TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
-55.51%
6.5%
0.0%
6 Months
-64.65%
7.1%
0.0%
1 Year
-88.67%
9.8%
0.0%
3 Years
-95.17%
14.2%
-20.2%

Highlights

Market Capitalization
43.9M
Book Value
- $2.15
Earnings Per Share (EPS)
-5.18
Wall Street Target Price
8.25
Profit Margin
0.0%
Operating Margin TTM
-4151.72%
Return On Assets TTM
-66.96%
Return On Equity TTM
-1766.94%
Revenue TTM
1.8M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
182.5%
Gross Profit TTM
355.0K
EBITDA
-140.3M
Diluted Eps TTM
-5.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.54
EPS Estimate Next Year
-1.68
EPS Estimate Current Quarter
-0.7
EPS Estimate Next Quarter
-0.71

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Bioxcel Therapeutics(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
4
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 617.39%

Current $1.15
Target $8.25

Technicals Summary

Sell

Neutral

Buy

Bioxcel Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bioxcel Therapeutics
Bioxcel Therapeutics
-11.36%
-64.65%
-88.67%
-95.17%
-89.36%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bioxcel Therapeutics
Bioxcel Therapeutics
NA
NA
NA
-2.54
-17.67
-0.67
NA
-2.15
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bioxcel Therapeutics
Bioxcel Therapeutics
Buy
$43.9M
-89.36%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Bioxcel Therapeutics

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 341.0K → 582.0K (in $), with an average increase of 22.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -22.25M → -26.79M (in $), with an average decrease of 20.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 150.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 281.7%

Institutional Holdings

  • FMR Inc

    6.65%

  • BlackRock Inc

    3.54%

  • Vanguard Group Inc

    2.93%

  • Ameriprise Financial Inc

    1.54%

  • State Street Corporation

    1.24%

  • Geode Capital Management, LLC

    1.22%

Company Information

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Organization
Bioxcel Therapeutics
Employees
74
CEO
Dr. Vimal D. Mehta Ph.D.
Industry
Health Technology

Discover More

FAQs